摘要
目的制备贴合人体组织、安全有效的可吸收性乳腺癌术后放疗指示标记夹,同时为其他组织修复标记材料的设计和构建提供理论指导。方法以外消旋丙交酯(DLLA)、三亚甲基碳酸酯(TMC)为原料,一定条件下,将DLLA与TMC共聚合成共聚物PDT[poly-(D,L-lactide-co-TMC)],将PDT样品与制备的磁性纳米Fe_(3)O_(4)颗粒通过溶液共混,制备出分散性良好的磁性纳米复合材料。分别在X射线及CT下观察材料显影效果,并结合所研究材料的表征,筛选最佳磁性纳米Fe_(3)O_(4)颗粒浓度。结果PDT/Fe_(3)O_(4)复合材料电镜下具有较好的均一性,材料的力学强度随着磁性纳米Fe_(3)O_(4)颗粒的质量分数变化而改变,弹性模量最高为399.66MPa,对应Fe_(3)O_(4)颗粒的质量分数为0.5%,最低为160.34MPa,对应Fe_(3)O_(4)颗粒的质量分数为0%;材料与乳房局部组织的CT值有阳性差异,最大CT值为1762.2HU,利于医学影像学显影。结论PDT/Fe_(3)O_(4)复合材料具有良好的生物可吸收性,具备良好的影像学显影功能,降解全程满足放疗周期,可用作乳腺癌术后放疗指示标记夹。
Objective To prepare a safe and effective absorbable radiotherapy indicator marker clip that fits human tissues,and to provide theoretical guidance for the design and construction of other marker materials.Methods D,L-Lactide(DLLA)and trimethylene carbonate(TMC)were copolymerized under certain conditions and purified by dissolution and precipitation for many times to form Poly-(D,L-lactide-co-TMC,PDT).PDT samples were blended with prepared magnetic nano-Fe_(3)O_(4)particles in dichloromethane solvent,stirred and precipitated to prepare magnetic nanocomposites with good dispersion.X-ray and CT were used to study the development effect of the materials,and combined with the characterization of the materials,the optimum concentration of magnetic nano-Fe_(3)O_(4)particles was screened.Results The composite material had good homogeneity under the electron microscope and the mechanical strength of the material changes with the mass fraction of magnetic nano-Fe_(3)O_(4)particles.The highest elastic modulus was 399.66 MPa,with 0.5%mass fraction of Fe_(3)O_(4)particles and the lowest was 160.34 MPa with 0%mass fraction of Fe_(3)O_(4)particles;the CT value of the material had positive difference with the local breast tissue,with the maximum CT value of 1762.2 HU,which was conducive to development.Conclusion PDT/Fe_(3)O_(4)complex has good bio-absorbability and good imaging function and can be used as the indicative marker clip for post-operative radiotherapy of breast cancer.
作者
陆森
罗炜
叶萍
刘婷
李思雯
韩宝三
李玉林
LU Sen;LUO Wei;YE Ping;LIU Ting;LI Si-wen;HAN Bao-san;LI Yu-lin(Department of General Surgery,Xinhua Hospital,Affiliated with Shanghai Jiao Tong University School of Medicine Shanghai 200092,China;Institute of Biliary Tract Disease,Shanghai Jiao Tong University School of Medicine,Shanghai 200092,China;Shanghai Key Laboratory,Biliary Tract Disease Research,Shanghai 200092,China;Engineering Research Centre for Biomedical Materials of Ministry of Education,East China University of Science and Technology,Shanghai 200237,China;School of Medical Instrument and Food Engineering,University of Shanghai for Science and Technology,Shanghai 200093,China;Department of Inpatient,Jiahui International Hospital,Shanghai 200233,China)
出处
《中华肿瘤防治杂志》
CAS
北大核心
2021年第1期42-47,共6页
Chinese Journal of Cancer Prevention and Treatment
